Inflammation 2005 - Seventh World Congress. Rheumatoid arthritis and cell signaling.
Novel targets for antirheumatic therapy were discussed including synoviocyte CD97 and the T-cell co-receptor CTLA-4: an immunoglobulin fusion protein of CTLA-4 (abatacept (Bristol-Myers Squibb Co)) has recently been revealed to be a well-tolerated and effective therapeutic agent for rheumatoid arthritis. Furthermore, cell-signaling molecules were a major topic, and cytoplasmic adaptors of toll-like receptor responses, the kinases JNK and Lyn and the macrophage surface molecule CD200 were considered as potential targets for novel therapies.